ERBB2 and breast carcinoma: Notably, studies on HER-2-positive SGCs employ treatment regimens similar to those used for breast cancer, such as HER-2 antibodies (trastuzumab, pertuzumab, and TDM-1) in combination with taxane-based chemotherapy.